Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Research and Development Activities
4.2.2 Technological Advancements in Toxicology Drug Screening
4.2.3 Rise in Demand for Toxicology Drug Screening in the Pharmaceutical and Biotechnology industries
4.3 Market Restraints
4.3.1 Longer Time for Sample Testing
4.3.2 Regulatory Issues Regarding Approval of Healthcare Molecule
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Testing Type
5.1.1 In vitro
5.1.2 In vivo
5.1.3 In silico
5.2 By Application
5.2.1 Immunotoxicity
5.2.2 Systemictoxicity
5.2.3 Developmental and Reproductive Toxicity (DART)
5.2.4 Endocrine Disruption
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Agilent Technologies, Inc
6.1.3 Covance, Inc (LabCorp)
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Eurofins Scientific
6.1.6 GE Healthcare
6.1.7 BioReliance, Inc. (Sigma-Aldrich)
6.1.8 Thermo Fisher Scientific, Inc
6.1.9 Quest Diagnostics
6.1.10 Enzo Life Sciences, Inc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS